Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $48.13 in the prior trading day, Avidity Biosciences Inc (NASDAQ: RNA) closed at $50.47, up 4.86%. In other words, the price has increased by $4.86 from its previous closing price. On the day, 1.69 million shares were traded. RNA stock price reached its highest trading level at $51.35 during the session, while it also had its lowest trading level at $48.045.
Ratios:
Our goal is to gain a better understanding of RNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.26 and its Current Ratio is at 9.26. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.Bernstein initiated its Outperform rating on June 24, 2025, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 03 ’25 when Mosbrooker Eric sold 6,562 shares for $45.38 per share. The transaction valued at 297,771 led to the insider holds 55,000 shares of the business.
Hughes Steven George sold 2,208 shares of RNA for $89,601 on Sep 22 ’25. The Chief Medical Officer now owns 38,867 shares after completing the transaction at $40.58 per share. On Sep 15 ’25, another insider, McCarthy Teresa, who serves as the Chief Human Resources Officer of the company, sold 15,000 shares for $41.41 each. As a result, the insider received 621,142 and left with 97,130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 7363741696 and an Enterprise Value of 5315124736. For the stock, the TTM Price-to-Sale (P/S) ratio is 686.28 while its Price-to-Book (P/B) ratio in mrq is 5.11. Its current Enterprise Value per Revenue stands at 495.398 whereas that against EBITDA is -10.246.
Stock Price History:
The Beta on a monthly basis for RNA is 0.91, which has changed by -0.008037925 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 10.75%, while the 200-Day Moving Average is calculated to be 45.95%.
Shares Statistics:
The stock has traded on average 3.19M shares per day over the past 3-months and 1476350 shares per day over the last 10 days, according to various share statistics. A total of 145.90M shares are outstanding, with a floating share count of 131.53M. Insiders hold about 9.85% of the company’s shares, while institutions hold 91.03% stake in the company. Shares short for RNA as of 1759190400 were 20751004 with a Short Ratio of 6.51, compared to 1756425600 on 17571891. Therefore, it implies a Short% of Shares Outstanding of 20751004 and a Short% of Float of 14.330000000000002.
Earnings Estimates
A comprehensive evaluation of Avidity Biosciences Inc (RNA) is underway, with the input of 15.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.27, with high estimates of -$0.61 and low estimates of -$2.36.
Analysts are recommending an EPS of between -$3.33 and -$6.26 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.97, with 16.0 analysts recommending between -$3.24 and -$7.31.
